PROCEPT BioRobotics Corporation

XNASHealth care

Last traded price · USD

$19.79

−8.63%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:07 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $21.66
Volume: 5,519
Day's high: —
Day's low: —

In brief

PROCEPT BioRobotics Corporation is a health care company listed on Nasdaq, valued at about $1.13B.
Its shares closed at $21.66 on 4 Nov 2026, down 38.1% over the past year.
From India you can buy PRCT in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy PROCEPT BioRobotics Corporation (PRCT) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole PRCT share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade PRCT options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: +23.7% (SPY −1.6%, XLV +13.5%). 3 months: +12.0% (SPY −0.4%, XLV +15.5%). 1 year: −38.1% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: PRCT, SPY and XLV · as of 4 Nov 2026
5.6 days to cover short interest
7.5M shares were sold short at the 15 Oct 2026 settlement, 13.1% of the 57.3M shares outstanding; covering them would take 5.6 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Volume 2.3× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 2.8M shares was 2.3× the average of the 30 sessions before it (1.2M), as the price rose 7.4%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
Above its 50-day average, below its 200-day
The 4 Nov 2026 close of $21.66 was 12.0% above its 50-day average ($19.34) and 6.5% below its 200-day average ($23.17). It has closed below the 200-day for 446 sessions, since 28 Jan 2025. The 50-day average crossed below the 200-day on 3 Mar 2025, 422 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
23% of the way up its 52-week range
Closed at $21.66 on 4 Nov 2026: 43.2% below the 52-week high of $38.11 (5 Dec 2025) and 30.0% above the low of $16.67 (24 Jul 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+23.7%

6 months−12.7%

1 year−38.1%

5 years−50.7%

Newswire

About

PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.

Website

Notable moves

October 28, 2024
+32.33%
August 21, 2024
+28.36%
April 27, 2023
−25.31%

PROCEPT BioRobotics Corporation

XNASHealth care

Last traded price · USD

$19.79

−8.63%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:07 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $21.66
Volume: 5,519
Day's high: —
Day's low: —

In brief

PROCEPT BioRobotics Corporation is a health care company listed on Nasdaq, valued at about $1.13B.
Its shares closed at $21.66 on 4 Nov 2026, down 38.1% over the past year.
From India you can buy PRCT in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy PROCEPT BioRobotics Corporation (PRCT) shares from India?

Do I need the price of a whole PRCT share to invest?

How much can I invest in US stocks in a year?

Can I trade PRCT options or futures?

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: +23.7% (SPY −1.6%, XLV +13.5%). 3 months: +12.0% (SPY −0.4%, XLV +15.5%). 1 year: −38.1% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: PRCT, SPY and XLV · as of 4 Nov 2026
5.6 days to cover short interest
7.5M shares were sold short at the 15 Oct 2026 settlement, 13.1% of the 57.3M shares outstanding; covering them would take 5.6 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Volume 2.3× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 2.8M shares was 2.3× the average of the 30 sessions before it (1.2M), as the price rose 7.4%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
Above its 50-day average, below its 200-day
The 4 Nov 2026 close of $21.66 was 12.0% above its 50-day average ($19.34) and 6.5% below its 200-day average ($23.17). It has closed below the 200-day for 446 sessions, since 28 Jan 2025. The 50-day average crossed below the 200-day on 3 Mar 2025, 422 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
23% of the way up its 52-week range
Closed at $21.66 on 4 Nov 2026: 43.2% below the 52-week high of $38.11 (5 Dec 2025) and 30.0% above the low of $16.67 (24 Jul 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+23.7%

6 months−12.7%

1 year−38.1%

5 years−50.7%

Newswire

About

Website

Notable moves

October 28, 2024
+32.33%
August 21, 2024
+28.36%
April 27, 2023
−25.31%

PROCEPT BioRobotics Corporation

PROCEPT BioRobotics Corporation in brief

Behind SPY and its sector fund XLV over 1 year

5.6 days to cover short interest

Volume 2.3× its 30-session average on 4 Nov 2026

Above its 50-day average, below its 200-day

23% of the way up its 52-week range

PROCEPT BioRobotics Corporation

PROCEPT BioRobotics Corporation in brief

Behind SPY and its sector fund XLV over 1 year

5.6 days to cover short interest

Volume 2.3× its 30-session average on 4 Nov 2026

Above its 50-day average, below its 200-day

23% of the way up its 52-week range